Latest & greatest articles for Serotonin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Serotonin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Serotonin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Serotonin

1. Selective Serotonin Reuptake Inhibitor Use May Increase the Risk of Dental Implant Failure

Selective Serotonin Reuptake Inhibitor Use May Increase the Risk of Dental Implant Failure UTCAT3400, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Selective Serotonin Reuptake Inhibitor Use May Increase the Risk of Dental Implant Failure Clinical Question Does history of selective serotonin reuptake inhibitor (SSRI) use affect implant success as compared to patients with no history of SSRI use? Clinical Bottom Line (...) For a patient with a history of selective serotonin reuptake inhibitor use, evidence shows an association for an increased risk of dental implant failure. However, evidence from a prospective cohort study would be needed to show a true “cause-effect” relationship. Clinicians and patients should be aware that use of certain medications may affect bone homeostasis and osseointegration of dental implants. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient

2019 UTHSCSA Dental School CAT Library

2. Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines

Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines - GOV.UK GOV.UK uses cookies to make the site simpler. Search Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines Tapentadol may increase seizure risk in patients taking other medicines that lower seizure (...) threshold, for example, antidepressants and antipsychotics. Serotonin syndrome has also been reported when tapentadol is used in combination with serotoninergic antidepressants. Published 9 January 2019 Last updated 9 January 2019 — From: Therapeutic area: , , , Contents Advice for healthcare professionals: as for all opioid medicines, tapentadol can induce seizures tapentadol should be prescribed with care in patients with a history of seizure disorders or epilepsy tapentadol may increase seizure risk

2019 MHRA Drug Safety Update

3. Prestroke selective serotonin reuptake inhibitor use and functional outcomes after ischaemic stroke Full Text available with Trip Pro

Prestroke selective serotonin reuptake inhibitor use and functional outcomes after ischaemic stroke Selective serotonin reuptake inhibitors (SSRIs) have been implicated in contributing to recovery after acute ischaemic stroke. In particular, poststroke initiation of an SSRI has been demonstrated to improve motor recovery. The role of prestroke SSRI use on functional outcomes and stroke recovery is less clear. We aimed to examine the effect of prestroke SSRI use on metrics of hospitalisation

2018 Stroke and vascular neurology

4. Serotonin syndrome

Serotonin syndrome Serotonin syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Serotonin syndrome Last reviewed: February 2019 Last updated: January 2018 Summary Clinical manifestation of excess serotonin in the central nervous system, resulting from the therapeutic use or overdose of serotonergic drugs. Characterised by a triad of clinical features: neuromuscular excitation, autonomic effects, and altered (...) mental status. Better described as a spectrum of toxicity, ranging from mild to severe, rather than a 'syndrome'. Diagnosis is clinical and should be based on the Hunter Serotonin Toxicity Criteria (HSTC), of which clonus is a key diagnostic feature. Treatment is guided by the severity of toxicity and involves cessation of the drug(s), supportive care, and anti-serotonergic drugs in select patients. Definition An excess of synaptic serotonin in the central nervous system that clinically manifests

2018 BMJ Best Practice

5. Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological

Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity (...) psychological treatments as defined by the National Institute for Health and Care Excellence guidelines Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines Buszewicz M, Cape J, Serfaty M, Shafran R, Kabir T, Tyrer P

2017 Health Technology Assessment (HTA) Database.

6. The Effects of Serotonin in Immune Cells Full Text available with Trip Pro

The Effects of Serotonin in Immune Cells Serotonin [5-hydroxytryptamine (5-HT)] plays an important role in many organs as a peripheral hormone. Most of the body's serotonin is circulating in the bloodstream, transported by blood platelets and is released upon activation. The functions of serotonin are mediated by members of the 7 known mammalian serotonin receptor subtype classes (15 known subtypes), the serotonin transporter (SERT), and by covalent binding of serotonin to different effector (...) proteins. Almost all immune cells express at least one serotonin component. In recent years, a number of immunoregulatory functions have been ascribed to serotonin. In monocytes/macrophages, for example, serotonin modulates cytokine secretion. Serotonin can also suppress the release of tumor necrosis factor-α and interleukin-1β by activating serotonin receptors. Furthermore, neutrophil recruitment and T-cell activation can both be mediated by serotonin. These are only a few of the known

2017 Frontiers in cardiovascular medicine

7. Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case–Control Study in Australia Full Text available with Trip Pro

Risk of Hip Fracture in Older People Using Selective Serotonin Reuptake Inhibitors and Other Psychoactive Medicines Concurrently: A Matched Case–Control Study in Australia Few studies have assessed the risk of hip fracture following concurrent use of psychoactive medicines, and none has investigated combinations with selective serotonin reuptake inhibitors.To assess the risk of hip fracture in older people as a result of concurrent use of selective serotonin reuptake inhibitors and other (...) differed from the sum of individual effects.There were 8828 cases and 35,310 controls. The median age of subjects was 88 years and 63% were women. The risk of hip fracture was elevated for all medicines assessed individually, most notably selective serotonin reuptake inhibitors (initiation: odds ratio [OR] = 2.7, 95% confidence interval [CI] 2.1, 3.6) and opioids (initiation: OR = 2.3, 95% CI 1.9, 2.9). Combinations associated with an increased odds of hip fracture included addition of benzodiazepines

2017 Drugs - real world outcomes

8. Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study. Full Text available with Trip Pro

Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study. Objective To evaluate whether the association between maternal periconceptional use of selective serotonin reuptake inhibitors (SSRIs) and increased risk of congenital heart defects in offspring is modified by maternal or infant genetic variants in folate, homocysteine, or transsulfuration pathways.Design

2017 BMJ

9. Causes and risk factors: Increased serotonin 1A receptor availability in the raphe nuclei predicts future suicidal behaviour

Causes and risk factors: Increased serotonin 1A receptor availability in the raphe nuclei predicts future suicidal behaviour Increased serotonin 1A receptor availability in the raphe nuclei predicts future suicidal behaviour | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Increased serotonin 1A receptor availability in the raphe nuclei predicts future suicidal behaviour Article Text Electronic pages Causes and risk factors Increased

2017 Evidence-Based Mental Health

11. Selective serotonin reuptake inhibitor (SSRI) toxicity - emergency management

Selective serotonin reuptake inhibitor (SSRI) toxicity - emergency management

2017 DynaMed Plus

12. Selective serotonin-norepinephrine reuptake inhibitor (SNRI) toxicity - emergency management

Selective serotonin-norepinephrine reuptake inhibitor (SNRI) toxicity - emergency management

2017 DynaMed Plus

13. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. Full Text available with Trip Pro

Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.  To compare differences in mortality between women concomitantly treated with tamoxifen and selective serotonin reuptake inhibitors (SSRIs) that are potent inhibitors of the cytochrome-P450 2D6 enzyme (CYP2D6) versus tamoxifen and other SSRIs. Population based cohort study. Five US databases covering individuals enrolled in private and public health insurance programs

2016 BMJ

14. Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy (Abstract)

Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy To examine whether using selective serotonin reuptake inhibitors and selective serotonin-norepinephrine reuptake inhibitors in pregnancy is associated with an increased risk of postpartum hemorrhage.We conducted a population-based cohort study including 225,973 women with 322,224 pregnancies in British Columbia, Canada, between 2002 and 2011. Women were categorized according to whether they had late (...) -pregnancy exposure (at least 15 of the last 30 days of pregnancy), midpregnancy exposure (in the last 5 months of pregnancy but not the final 30 days), or no exposure. Postpartum hemorrhage was identified using International Classification of Diseases (9th and 10th Revisions) codes in data on all hospitalizations.We found an increased risk of postpartum hemorrhage associated with exposure to an serotonin-norepinephrine reuptake inhibitor in the final month of pregnancy after adjustment for potential

2016 EvidenceUpdates

15. The role of electroencephalography in the diagnosis of serotonin syndrome Full Text available with Trip Pro

The role of electroencephalography in the diagnosis of serotonin syndrome Serotonin syndrome is a potentially life-threatening side-effect of agents that enhance synaptic serotonin levels. With the increasing use of serotoninergic agents greater awareness of serotonin syndrome is necessary, including the potential for drug interactions with serotoninergic agents to produce serotonin syndrome. Clinical presentation ranges from mild reactions to a severe toxic state involving generalized tonic (...) -clonic seizures, fevers exceeding 40℃ or coma. This case highlights the necessity of considering serotonin syndrome alongside other differential diagnoses: neuroleptic malignant syndrome, infectious cause, atypical seizures and delirium tremens, in the setting of altered mental state with abnormal neurology. It highlights the potential diagnostic use of electroencephalography in supporting a diagnosis of serotonin syndrome.

2016 Journal of the Intensive Care Society

16. First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. (Abstract)

First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. 26200755 2015 08 17 2015 08 13 1533-4406 373 7 2015 Aug 13 The New England journal of medicine N. Engl. J. Med. First-Trimester Use of Selective Serotonin-Reuptake Inhibitors and the Risk of Birth Defects. 686 10.1056/NEJMx150030 eng Published Erratum 2015 07 22 United States N Engl J Med 0255562 0028-4793 N Engl J Med. 2007 Jun 28;356(26):2675-83 17596601 2015 7 23 6 0 2015 7 23 6 0 2015 7 23 6 1

2015 NEJM

17. Systematic review and meta-analysis: Exposure to selective serotonin reuptake inhibitors in late pregnancy increases the risk of persistent pulmonary hypertension of the newborn, but the absolute risk is low Full Text available with Trip Pro

Systematic review and meta-analysis: Exposure to selective serotonin reuptake inhibitors in late pregnancy increases the risk of persistent pulmonary hypertension of the newborn, but the absolute risk is low Exposure to selective serotonin reuptake inhibitors in late pregnancy increases the risk of persistent pulmonary hypertension of the newborn, but the absolute risk is low | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can (...) to selective serotonin reuptake inhibitors in late pregnancy increases the risk of persistent pulmonary hypertension of the newborn, but the absolute risk is low Article Text Child health Systematic review and meta-analysis Exposure to selective serotonin reuptake inhibitors in late pregnancy increases the risk of persistent pulmonary hypertension of the newborn, but the absolute risk is low Free Nancy Byatt , Marlene P Freeman Statistics from Altmetric.com Commentary on: Grigoriadis S , Vonderporten EH

2015 Evidence-Based Nursing

18. CPIC Guideline for Selective Serotonin Reuptake Inhibitors and CYP2D6 and CYP2C19

CPIC Guideline for Selective Serotonin Reuptake Inhibitors and CYP2D6 and CYP2C19 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors JKHicks 1 ,JRBishop 2 ,KSangkuhl 3 ,DJM€ uller 4 ,YJi 5 ,SGLeckband 6 ,JSLeeder 7 ,RLGraham 8 , DLChiulli 9 ,ALLerena 10 ,TCSkaar 11 ,SAScott 12 ,JCStingl 13 ,TEKlein 3 ,KECaudle 14 andAGaedigk 7 Selective serotonin reuptake inhibitors (SSRIs) are primary (...) with the selective serotonin reuptake inhibitors (SSRIs) are associated with CYP2D6 or CYP2C19 polymorphisms. 1 The purpose of this guideline is to provide information to allow the interpretation of existing CYP2D6 and/or CYP2C19 genotype tests to guide SSRI dosing, particu- larly focusing on ?uvoxamine, paroxetine, citalopram, escitalo- pram, and sertraline. Other clinical variables that may in?uence SSRI therapy as well as genotyping cost-effectiveness are beyond the scope of this article. CPIC guidelines

2015 Clinical Pharmacogenetics Implementation Consortium

19. Selective serotonin reuptake inhibitors for the treatment of depression in adults

Selective serotonin reuptake inhibitors for the treatment of depression in adults This document prepares the clinician to discuss scientific data with the patient so they can make an informed decision together. What are selective serotonin reuptake inhibitors (SSRIs) for? ? SSRIs are a class of medications that are taken daily to reduce the symptoms of depression. These medications (Citalopram [Celexa®], Escitalopram [Cipralex®], Fluoxetine [Prozac®], Fluvoxamine [Luvox®], Paroxetine [Paxil® (...) ], Sertraline [Zoloft®]) act by selectively inhibiting the uptake of serotonin. Among individuals with depressive symptoms, who might consider taking SSRIs? ? Adults diagnosed with moderate to severe unipolar depression. Diagnosis can be made using the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)* Why do patient preferences matter when making this decision? ? There are pros and cons to taking this medication: PROS: Individuals with moderate to severe depression who take SSRIs for 4-8 weeks

2014 Cancer Council Australia

20. Cohort study: Late pregnancy use of selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors is associated with increased risk of postpartum haemorrhage

Cohort study: Late pregnancy use of selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors is associated with increased risk of postpartum haemorrhage Late pregnancy use of selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors is associated with increased risk of postpartum haemorrhage | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your (...) serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors is associated with increased risk of postpartum haemorrhage Article Text Midwifery Cohort study Late pregnancy use of selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors is associated with increased risk of postpartum haemorrhage Cande V Ananth , Alexander M Friedman Statistics from Altmetric.com Commentary on: Palmsten K , Hernández-Díaz S , Huybrechts KF , et al . Use

2014 Evidence-Based Nursing